Fig. 1

Flowchart of patient enrollment and study design. EGFR-TKI resistant NSCLC patients who received ICI plus chemotherapy were enrolled. The whole cohort include 60 patients and information of clinical characteristics and outcomes were collected. Among them, 24 patients were considered as PBMC cohort whose PBMC samples at baseline and 2 cycles of ICI plus chemotherapy were collected. All PBMC samples were detected through full spectrum flow cytometry and a 23-color-antibody panel was designed to profile the immune cells in peripheral blood. Abbreviations: NLR, neutrophil to lymphocyte ratio. PLR, platelet-to-lymphocyte ratio. Pre-tx, pre-treatment. On-tx, on treatment. PBMC, peripheral blood mononuclear cell. ICPs, immune checkpoint proteins. MFI, mean fluorescence intensity. EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor. NSCLC, non-small cell lung cancer. ICI, immune checkpoint inhibitor. ORR, objective response rate. CB, clinical benefits. PFS, progression-free survival